Abbott Laboratories
NYSE:ABT
Gross Margin
Abbott Laboratories
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.1B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.5B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.5B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
142.7B USD |
65%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.5B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
50.9B EUR |
39%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.7B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.1B USD |
79%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42B USD |
61%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
281.3B CNY |
61%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.7B USD |
59%
|
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Abbott Laboratories's most recent financial statements, the company has Gross Margin of 56.1%.
You don't have any saved screeners yet